The survey, which included 1,100 PCMs who also identify with a mental health condition and 302 health professionals who treat neurological conditions, found that nearly all health professionals (91%) and two-thirds of health professionals Health (67%) believe that those who are better able to manage their stress and mental health conditions are also better able to manage migraine.
“Migraine is complex and has the ability to disrupt a person’s life, relationships and sense of well-being, which in turn can affect their mental health,” he said. judy hoPh.D., triple board certified clinical and forensic neuropsychologist and former co-host of The doctors. “The Migraine and Mental Health Connection Survey showed that people with migraine and health professionals are aligned in recognizing that the unpredictable and disabling nature of migraine attacks often creates worry and anxiety that can add difficulty to the ability to control migraine and further affect your health mental. This is often referred to as a “vicious cycle” between migraine and mental health. It’s important for people with migraine to understand that improving mental health can lead to better migraine outcomes and vice versa.”
Conversations about migraine and mental health
A vital step in improving those results is talking to a trusted HCP. Two-thirds of PwMs said it is important to discuss mental health with the HCP treating their migraine, and nearly 60% reported that they brought up the topic themselves, although most wish their HCP would initiate the conversation. The survey found a marked mismatch between HCPs and PwMs on this topic, with 70% of HCPs saying they ask about mental health conditions often, if not always.
“Closing gaps in communication between healthcare professionals and their patients can help improve migraine management and mental health,” he said. Larry Newman, MD, professor of neurology at NYU Grossman School of Medicine and president of AMF. “I hope the findings of this survey encourage people with migraine to feel empowered to talk about their pain and have deeper, more meaningful conversations about migraine and mental health without worrying about stigma. These are important conversations that both people with migraine as health professionals should initiate at each visit.
Interestingly, the survey found that HCPs underestimate the percentage of PwMs suffering from depression and anxiety disorders. While 57% and 50% of PwM report having been diagnosed with an anxiety disorder or depression, respectively, HCPs estimate that these conditions occur in only 29% and 30% of patients, respectively.”
Treatment Approach
Both PwM (87%) and HCP (94%) believe mental health would benefit from better migraine control. The top three mental health treatments recommended by health professionals are medications (83%), psychotherapy or cognitive behavioral therapy (71%), and relaxation therapy (70%). But PcMs do not report using these techniques as often (58%, 28%, and 26%, respectively). Nearly all HCPs (91%) and more than half of PwMs surveyed (54%) feel that migraine management needs to be more flexible in tailoring treatment to patient needs. In addition, almost all PwMs feel that it is equally important to treat migraine and mental health and want their HCP to consider these dual priorities in their treatment plan.
“At Biohaven, we are motivated to help the millions of migraine sufferers better manage their attacks,” said Vlad Koric, MD, CEO and Chairman of the Board of Biohaven. “This survey conducted by the American Migraine Foundation allows us to learn more about the perspectives of HCPs and their migraine patients as we work to better understand the complexities of migraine and its impact on mental health.”
To learn more about migraine and its impact on mental health, visit www.americanmigrainefoundation.org.
This survey was conducted with the support of Biohaven Pharmaceutical Holding Company Ltd.
About the survey
the Migraine and Mental Health connection survey was an online quantitative opinion survey conducted by the American Migraine Foundation and funded by Biohaven Pharmaceutical Holding Company Ltd. The survey was conducted between April and May 2022 and included responses from 1,100 people with migraine (PwM) and a mental health condition, and 302 healthcare professionals (HCPs) treating neurological conditions (including 50 neurologists, 50 headache specialists, and 202 general practitioners).
about migraine
Nearly 40 million people in the US suffer from migraine and the World Health Organization ranks migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including moderate to severe throbbing headaches that may be associated with nausea or vomiting and/or sensitivity to sound (phonophobia) and sensitivity to light. light (photophobia). There is a significant unmet need for new treatments, as more than 90 percent of people with migraine are unable to work or function normally during an attack.
About the American Migraine Foundation
The American Migraine Foundation provides education, support, and resources for the millions of men, women, and children living with migraine. Our mission is to advance migraine research, promote patient advocacy, and expand access to care for patients around the world. Migraine and other disabling conditions that cause severe headaches affect more than 39 million people worldwide. the United States only. By educating caregivers and giving patients the tools to advocate for themselves, we have cultivated a movement that gives the migraine community a collective voice. Working closely with migraine and headache experts at our partner organization, the American Headache Society, we educate caregivers and give patients the tools to advocate for themselves, cultivating a movement that gives a collective voice to the community. of migraines. For more information please visit www.americanmigrainefoundation.org.
About Biohaven
Biohaven is a commercial-stage global biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation™ portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura® for the acute treatment of migraine with or without aura, and prophylaxis of migraine). episodic migraine in adults who have at least four migraine attacks per month) and a broad portfolio of late-stage product candidates across five distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; and MPO inhibition for amyotrophic lateral sclerosis; Kv7 (Kv7) ion channel activators for focal epilepsy and neuronal hyperexcitability, and myostatin inhibitors for neuromuscular diseases. More information about Biohaven is available at www.biohavenpharma.com.
NURTEC®, NURTEC ODT and VYDURA are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Neuroinnovation and NOJECTION are trademarks of Biohaven Pharmaceutical Holding Company Ltd.
Tweet it: The American Migraine Foundation survey shows that almost all people with migraine and health professionals believe that migraine and mental health have a significant impact on each other: https://www.biohavenpharma.com/about-biohaven/media-resources
Media contact
mike beyer
sam brown inc.
[email protected]
312-961-2502
American Migraine Foundation Contact
heather phillips
[email protected]
SOURCE Biohaven Pharmaceutical Holding Company Ltd.
.
